Please upgrade your browser.
A new study from the Mayo Clinic hints at a promising treatment for late-stage cancer patients—but a real breakthrough could be years away.
Interleukin-6 (IL-6) plays a contributory role in the progression and severity of many forms of cancer; it however remains unclear whether the relevance between circulating IL-6 and cancer is causal.
Match the official cancer awareness color with its disease awareness month using this infographic.
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.
Learn more about a type of kidney cancer called advanced renal cell carcinoma (aRCC) and the pathways involved in the disease in this animated whiteboard...
This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.
Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.
Everolimus is a mTOR inhibitor that demonstrates antitumor and antiangiogenic activities.
Supported by funding from the ASCO Young Investigator Award from the Kidney Cancer Association. A research team led by Mayo Clinic oncologists has found a new way to...
Currently, there are no treatment options in the setting of recurrent or unresectable RCC IVC-TT. Even though RCC may be resistant to conventionally fractionated radiation therapy, hypofractionated radiation has shown excellent control rates for both primary and metastatic RCC.
|Powered by NeonCRM|